HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Human antigen R (HuR) is an RNA-binding protein overexpressed in cancers, correlating with aggressive disease and poor prognosis.
• HuR inhibition demonstrates significant anticancer activity, with small-molecule inhibitors offering advantages over genetic methods.
• Non-small cell lung cancer (NSCLC) serves as a model to investigate novel therapeutic strategies targeting HuR.

Purpose of the Study:

• To evaluate the antitumor activity of CMLD-2, a small-molecule inhibitor targeting HuR.
• To assess the efficacy of CMLD-2 in NSCLC cell lines in vitro.
• To determine the molecular mechanisms underlying CMLD-2's effects on cancer cells.

Main Methods:

• In vitro testing of CMLD-2 on NSCLC cell lines (H1299, A549, HCC827, H1975) and normal human fibroblasts.
• Analysis of cell-cycle progression, apoptosis, mRNA and protein expression levels.
• Assessment of mitochondrial function and caspase activation.

Main Results:

• CMLD-2 induced dose-dependent cytotoxicity, G1 cell-cycle arrest, and apoptosis in NSCLC cells.
• CMLD-2 decreased HuR mRNA and HuR-regulated protein expression (Bcl2, p27, cyclin E, Bcl-XL) in tumor cells, with less impact on normal cells.
• Treatment led to increased Bax expression, mitochondrial perturbation, and activation of caspase-9, caspase-3, and PARP cleavage in tumor cells.

Conclusions:

• CMLD-2 exhibits significant antitumor activity against NSCLC by targeting HuR.
• The compound demonstrates a favorable therapeutic window, with greater effects on tumor cells than normal cells.
• CMLD-2 represents a promising HuR-targeted therapeutic agent for potential lung cancer treatment.